LFCR (Lifecore Biomedical) Shares Outstanding (EOP): 37.48 Mil (As of Mar. 2026)


LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.97
GF Value $6.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Shares Outstanding (EOP)?

Lifecore Biomedical LFCR -3.78% 55 Shares Outstanding (EOP) is 37.48 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Lifecore Biomedical's shares outstanding for the quarter that ended in Mar. 2026 was 37.48 Mil.

Lifecore Biomedical's quarterly shares outstanding stayed the same from Dec. 2025 (37.48 Mil) to Mar. 2026 (37.48 Mil).

Lifecore Biomedical's annual shares outstanding increased from May. 2024 (30.56 Mil) to May. 2025 (37.03 Mil). It means Lifecore Biomedical issued new shares from May. 2024 to May. 2025 .


Lifecore Biomedical  (NAS:LFCR) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Lifecore Biomedical Shares Outstanding (EOP) Related Terms


Lifecore Biomedical Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Shares Outstanding (EOP) Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.33 29.51 29.51 30.56 37.03

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.03 37.03 37.47 37.48 37.48

LFCR vs ANIK, DERM, ASRT: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Shares Outstanding (EOP) falls into.


LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 37.48 Mil mean?
Lifecore Biomedical (LFCR) has a Shares Outstanding (EOP) of 37.48 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Shares Outstanding (EOP) too high?
Lifecore Biomedical's current Shares Outstanding (EOP) is 37.48 Mil. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Shares Outstanding (EOP) compare to ANIK and DERM?
Lifecore Biomedical's Shares Outstanding (EOP) of 37.48 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Shares Outstanding (EOP) is 37.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Shares Outstanding (EOP) is 37.48 Mil. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Shares Outstanding (EOP) is 37.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Shares Outstanding (EOP): 37.48 Mil
  • GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price
$6.52
GF Value